Doximity (DOCS) news
Recent news
Barclays raises target price to $27 from $20 for Doximity (DOCS.N)
Barclays PLC has raised its price target for Doximity, Inc. (DOCS.N) from $20 to $27, reflecting a more optimistic outlook for the healthcare technology company. The upgrade comes amid broader market stabilization and signs of growth in the healthcare IT sector. While the firm did not immediately…
AInvest Wire · Aug 21, 2026NYSE halt Doximity Inc A add info lst $33.250000
Doximity Inc. (DOCS) recently experienced a notable development as its stock was halted on the NYSE and subsequently added to the list at a price of $33.250000. This action follows the company’s continued operations in the medical information systems sector, where it provides networking and…
AInvest Wire · Aug 7, 2026NYSE halt Doximity Inc A add info lst $37.150000
The New York Stock Exchange has halted the trading of Doximity Inc. (DOCS) shares, with the last reported price set at $37.150000. The halt is currently under review, and no further details have been disclosed by the exchange or the company. Investors are advised to monitor official announcements…
AInvest Wire · Aug 7, 2026Doximity shares briefly doubled in value in premarket trading, last up 89% at $39
Doximity (NYSE: DOCS) shares surged nearly 89% in premarket trading, reaching $39 per share, marking a significant rebound for the healthcare technology company. The sharp increase follows a period of volatility, with the stock having declined by 62.2% over the past 12 months. Analysts suggest that…
AInvest Wire · Aug 7, 2026Canaccord Genuity raises target price to $36 from $30 for Doximity, Inc.
Canaccord Genuity has raised its price target for Doximity, Inc. (NYSE: DOCS) to $36 from $30, reflecting a revised outlook on the healthcare technology company’s valuation and growth prospects. The upgrade follows a post-earnings selloff, which the firm described as an overreaction to short-term…
AInvest Wire · Aug 7, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.